Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Net Income towards Common Stockholders: 2023-2024

Historic Net Income towards Common Stockholders for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$65.4 million.

  • Artiva Biotherapeutics' Net Income towards Common Stockholders fell 41.30% to -$16.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$61.9 million, marking a year-over-year change of. This contributed to the annual value of -$65.4 million for FY2024, which is 127.62% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Net Income towards Common Stockholders of -$65.4 million as of FY2024, which was down 127.62% from -$28.7 million recorded in FY2023.
  • Over the past 5 years, Artiva Biotherapeutics' Net Income towards Common Stockholders peaked at -$28.7 million during FY2023, and registered a low of -$65.4 million during FY2024.
  • Its 2-year average for Net Income towards Common Stockholders is -$47.0 million, with a median of -$47.0 million in 2023.
  • Data for Artiva Biotherapeutics' Net Income towards Common Stockholders shows a maximum YoY slumped of 127.62% (in 2024) over the last 5 years.
  • Artiva Biotherapeutics' Net Income towards Common Stockholders (Yearly) stood at -$28.7 million in 2023, then slumped by 127.62% to -$65.4 million in 2024.